Daphne Karydas
Director · Mineralys Therapeutics, Inc.
IndividualSelling only9 10b5-1 trades
- 2025
- Sep 17, 2026
- 6
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Daphne Karydas files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Brian Taylor Slingsby - $46.36M in MLYS purchases and sales in the last 12 months
- Jon Congleton - $15.64M in MLYS purchases and sales in the last 12 months
- RA CAPITAL MANAGEMENT, L.P. - $8.76M in MLYS purchases and sales in the last 12 months
- Adam Scott Levy - $5.36M in MLYS purchases and sales in the last 12 months
- David Malcom Rodman - $4.43M in MLYS purchases and sales in the last 12 months
- Eric Warren - $3.30M in MLYS purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Daphne Karydas?
Daphne Karydas is a corporate insider, tracked as Director of Mineralys Therapeutics, Inc. (MLYS). InsiderAlpha holds 6 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Daphne Karydas submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Daphne Karydas been buying or selling stock?
Recorded transactions: 0 open-market purchases and 5 open-market sales ($926K) across all tracked filings.
